{"id":35618,"date":"2018-04-17T19:50:38","date_gmt":"2018-04-17T17:50:38","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=35618"},"modified":"2018-04-17T19:58:49","modified_gmt":"2018-04-17T17:58:49","slug":"sanofi-cede-zentiva-ad-advent-international","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/sanofi-cede-zentiva-ad-advent-international\/","title":{"rendered":"Sanofi sells Zentiva to Advent International?"},"content":{"rendered":"<p>Sanofi would be close to an agreement with the company\u00a0<em>private equity<\/em> Advent International for the divestment of Zentiva, the European generics business unit. Cost of the operation: approximately 2 billion Euros. The word now passes to the board of directors of Sanofi, which could already approve the agreement at the meeting scheduled for the beginning of next week.<\/p>\n<p><a href=\"http:\/\/www.fedaiisf.it\/wp-content\/uploads\/2018\/01\/zentiva_brand.png\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-34295 alignright\" src=\"http:\/\/www.fedaiisf.it\/wp-content\/uploads\/2018\/01\/zentiva_brand.png\" alt=\"\" width=\"491\" height=\"244\" srcset=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2018\/01\/zentiva_brand.png 904w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2018\/01\/zentiva_brand-300x149.png 300w, https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2018\/01\/zentiva_brand-768x381.png 768w\" sizes=\"auto, (max-width: 491px) 100vw, 491px\" \/><\/a>This news comes after the company&#039;s withdrawals were made official <em>private equity<\/em> Nordic Capital and the Indian pharmaceutical company Torrent Pharma, the latter more accredited for the acquisition than the others\u00a0<em>competitor<\/em>. The sale of Zentiva is part of the pipeline rationalization plan started by Sanofi in 2016, with the disposal of Merial, the Animal Health Unit, subject to a\u00a0<em>asset swaps\u00a0<\/em>with Boehringer Ingelheim&#039;s Consumer Health.<\/p>\n<p>A few days ago, a company spokesman announced the sale of 12 pharmaceutical brands\u00a0<em>not core <\/em>to Cooper-Vemedia for 158 million euros.<\/p>\n<p>Zentiva is present in 50 countries and grossed 760 million euros last year, 4.9% less than in 2016. In addition to selling, however, Sanofi, in the first <em>quarter<\/em> of the year, it also made acquisitions: biotech Ablynx for $4.8 billion and hemophilia drug maker Bioverativ for $11.6 billion.<\/p>\n<p><a href=\"http:\/\/www.dailyhealthindustry.it\/sanofi-cede-zentiva-ad-advent-international-ID9560.html\" target=\"_blank\" rel=\"noopener\">Daily Health Industry \u2013 April 17, 2018<\/a><\/p>\n<p>Related news:\u00a0<a href=\"http:\/\/www.affaritaliani.it\/economia\/accordo-da-2-4-miliardi-francia-irlanda-sull-oncologia-535468.html\" target=\"_blank\" rel=\"noopener\">Shire, an Irish pharmaceutical company, to sell the oncology division to the French Servier for 2.4 billion<\/a><\/p>\n<p><a href=\"http:\/\/www.repubblica.it\/economia\/2018\/04\/17\/news\/farmaci_grandi_manovre_per_novartis_e_advent-194080931\/\" target=\"_blank\" rel=\"noopener\">Drugs, big maneuvers for Novartis and Advent<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Sanofi sarebbe vicina a un accordo con la societ\u00e0 di\u00a0private equity Advent International\u00a0 per la cessione di Zentiva, la business unit europea dei farmaci generici. Costo dell\u2019operazione: circa 2 miliardi di Euro. La parola ora passa al\u00a0consiglio di amministrazione di Sanofi, che gi\u00e0 nella riunione prevista per l\u2019inizio della prossima settimana potrebbe dare il placet &hellip;<\/p>","protected":false},"author":4,"featured_media":35620,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[53],"class_list":["post-35618","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-fusioniacquisizioni"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/35618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=35618"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/35618\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/35620"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=35618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=35618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=35618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}